CN111072611B - 一种苯并呋喃亚胺内酯衍生物的合成方法 - Google Patents
一种苯并呋喃亚胺内酯衍生物的合成方法 Download PDFInfo
- Publication number
- CN111072611B CN111072611B CN201911323588.3A CN201911323588A CN111072611B CN 111072611 B CN111072611 B CN 111072611B CN 201911323588 A CN201911323588 A CN 201911323588A CN 111072611 B CN111072611 B CN 111072611B
- Authority
- CN
- China
- Prior art keywords
- imine
- reaction
- benzofuran
- benzyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 benzofuran imine lactone Chemical class 0.000 title claims abstract description 19
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 238000010189 synthetic method Methods 0.000 title claims description 5
- 239000000758 substrate Substances 0.000 claims abstract description 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000003197 catalytic effect Effects 0.000 claims abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 239000011630 iodine Substances 0.000 claims abstract description 5
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 5
- 239000007800 oxidant agent Substances 0.000 claims abstract description 5
- 239000002841 Lewis acid Substances 0.000 claims abstract description 4
- 230000001590 oxidative effect Effects 0.000 claims abstract description 4
- 239000000654 additive Substances 0.000 claims abstract description 3
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical group OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 3
- UDHAWRUAECEBHC-UHFFFAOYSA-N 1-iodo-4-methylbenzene Chemical group CC1=CC=C(I)C=C1 UDHAWRUAECEBHC-UHFFFAOYSA-N 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N boron trifluoride etherate Substances FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 150000007517 lewis acids Chemical class 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 abstract description 2
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 abstract description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 229910052723 transition metal Inorganic materials 0.000 abstract description 2
- 150000003624 transition metals Chemical class 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001503 aryl iodides Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- UZNGGIDVCAOZQQ-UHFFFAOYSA-N 3h-2-benzofuran-1-imine Chemical compound C1=CC=C2C(=N)OCC2=C1 UZNGGIDVCAOZQQ-UHFFFAOYSA-N 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HJMZMZRCABDKKV-UHFFFAOYSA-M cyanoformate Chemical compound [O-]C(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-M 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 150000004548 gossypol derivatives Chemical class 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical group [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明公开了结构通式（I）所示的苯并呋喃亚胺内酯衍生物的合成方法，其以结构式（II）所示的邻烯烃苯甲酰胺类分子为底物，加入催化当量的碘试剂/氧化剂催化体系，或三价碘苯体系，以路易斯酸为添加剂，室温反应一步构建结构式（I）所示的苯并呋喃亚胺内酯化合物。本发明无需金属催化反应，避免了毒副作用大的过渡金属的使用；反应条件温和，可以在空气、室温条件下进行；反应时间短，30分钟内反应即可完成；操作简单，底物适用范围广。
Description
技术领域
本发明涉一种合成苯并呋喃亚胺内酯类化合物的方法，特别是一种基于烯烃的碳氧（C(sp 2 )-O）键形成反应，合成苯并呋喃亚胺内酯类化合物的新方法，属于有机合成技术领域。
背景技术
亚胺内酯类衍生物是一类重要的有机合成中间体，且具有较为广泛的生物活性，在生命科学和医药领域具有广阔的应用前景。例如：具有亚胺内酯结构的棉籽酚衍生物，具有更好的抗HIV-I型病毒活性；具有亚胺内酯结构罗丹明类的荧光检测剂可用于检测细胞内的多种小分子化合物及蛋白；具有亚胺内酯结构的除草剂。此外，亚胺内酯类化合物还可用于高分子材料聚酰亚胺和聚异酰亚胺的合成，进一步转化可以合成一些药物分子，例如丁苯肽，是治疗轻中度急性缺血性脑卒中的一类药物。
关于亚胺内酯的合成，最早可追溯到上个世纪80年代。日本的Yoshihiko Ito教授课题组 (J. Org. Chem.1982, 47, 741-743) 以ß-不饱和碳基化合物与异氰基化合物为起始原料，在化学计量的二乙基氯化铝的作用下通过[4+1]环加成反应得到3这种亚胺内酯类化合物，化合物3经过简单的还原，水解，可以得到γ-丁内酯类化合物5。这类结构是一些药物分子，例如苦薄荷素，竹柏内酯的基本骨架结构。但这种合成方法仅能得到有限的产物，且需要用到剧毒性的异氰基类化合物作为反应底物，限制了其应用。
近年来，以芳炔，异氰酸酯与醛酮为底物的“三组分合成法”被广泛应用于苯并呋喃亚胺内酯类化合物的合成，Yoshida (Angew. Chem., Int. Ed.2004, 43, 3935-3938;Tetrahedron2007, 63, 4793-4805; Angew. Chem., Int. Ed.2011, 50, 4488-4491),Stoltz (Heterocycles2012, 86, 933-940)和Nishihara (Organometallics2014, 33,3500-3507)课题组分别报道了芳炔、异氰酸酯与醛/酮、乙酸苯酯、氰基甲酸盐的三组分偶联反应，得到了苯并呋喃亚胺内酯类化合物。该方法有效扩展了亚胺内酯类化合物的范围，但仍然使用了剧毒性的异氰基化合物作为反应底物。
近年来，以邻炔烃苯甲酰胺为底物的分子内选择性环化反应，可代替羰基组分和芳炔，成为合成取代的邻烯烃苯并呋喃亚胺内酯的有效的合成方法（Org. Lett.2016, 18,4814-4817; Chem. Commun.2017, 53, 5279-5282; Org. Biomol. Chem.2019, 17,4335-4341）。但由于酰胺的两种互变结构以及炔烃的选择性，应用该类底物可能会得到四种结构类型的产物，选择性较差。且需要一些昂贵的金属，例如Au，Pa等作催化剂。
发明内容
本发明的目的是提供一种工艺简单、反应条件温和、选择性高的合成苯并呋喃亚胺内酯类化合物的新方法。
本发明实现过程如下：
一种苯并呋喃亚胺内酯衍生物的合成方法，
以结构式（II）所示的邻烯烃苯甲酰胺类分子为底物，加入催化当量的碘试剂/氧化剂催化体系，或三价碘苯体系，以路易斯酸为添加剂，室温反应一步构建结构式（I）所示的苯并呋喃亚胺内酯化合物，
其中：R选自苯基、苄基、C1~C7的烷基，或取代的苯基或苄基，所述取代的苯基或苄基中的取代基为C1~C7的烷基、C1~C7的烷氧基、卤素、硝基、三氟甲基；
R1选自氢、C1~C7的烷基、C1~C7的烷氧基、卤素、三氟甲基，硝基；
R2选自氢，C1~C7的烷基，C1~C7的烷氧基、卤素、三氟甲基，硝基、苯基、苄基，或取代的苯基或苄基，所述取代的苯基或苄基中的取代基为C1~C7的烷基、C1~C7的烷氧基、卤素、硝基、三氟甲基。
所述的氧化剂选自过硫酸氢钾，间氯过氧苯甲酸。
所述的路易斯酸选自三氟化硼乙醚，甲基磺酸，三氟乙酸。
所述的碘试剂为碘单质，以及碘化钾或芳基碘，所述芳基碘中的芳基为 C1-C7的烷基，C1-C7的烷氧基、卤素、硝基或乙酰基取代的苯基或萘基。
本发明的优点在于，无需金属催化反应，避免了毒副作用大的过渡金属的使用；反应条件温和，可以在空气、室温条件下进行；反应时间短，30分钟内反应即可完成；操作简单，底物适用范围广。
具体实施方式
下面通过实施例对本发明进行详述，但本发明并不限于这些实施例。
实施例1通式（I）中化合物I-1 的合成
向装有磁子的反应试管中加入对甲基碘苯（10 mol%），间氯过氧苯甲酸（1.5equiv）和乙腈（2.0 mL）。然后再加入邻烯烃苯甲酰胺底物（0.2 mmol, 1.0 equiv），三氟化硼乙醚（1.5 equiv）。反应混合物室温条件下继续搅拌30分钟。 通过薄层色谱检测反应过程。反应完成后，将反应液直接湿法上样，通过1/5的碱性氧化铝，4/5的硅胶（200-300目）柱快速纯化，得到苯并呋喃亚胺内酯类化合物I-1。产物结构经1H NMR, 13C NMR 和HRMS确证。
产物结构表征：
(Z)-3-methylene-N-phenylisobenzofuran-1(3H)-imine (I-1). Colorlessoil (39.8 mg, 90%); 1H NMR (400 MHz, CDCl3) δ 7.98 (dt, J = 7.6, 1.2 Hz, 1H),7.68 – 7.58 (m, 1H), 7.58 – 7.48 (m, 1H), 7.45 – 7.31 (m, 3H), 7.16 (tt, J =6.8, 2.0 Hz, 1H), 5.00 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 155.1, 153.9,145.7, 136.2, 132.2, 130.8, 130.2, 128.8 (2C), 124.7, 123.7 (2C), 123.6,120.3, 87.2; HRMS: [M+H]+ calcd for C15H11NO 222.0913, found 222.0912。
实施例2
使用与实施例1相同方法，通过改变底物结构，可以得到下述化合物。
(Z)-N-(2,6-dimethylphenyl)-3-methyleneisobenzofuran-1(3H)-imine (I-2). Colorless oil (41.5 mg, 83%); 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 6.8Hz, 1H), 7.63 (t, J = 7.6 Hz, 2H), 7.59 – 7.52 (m, 1H), 7.08 (d, J = 7.6 Hz,2H), 6.97 (t, J = 7.6 Hz, 1H), 4.97 – 4.89 (m, 2H), 2.17 (s, 6H); 13C NMR (100MHz, CDCl3) δ 154.8, 153.1, 144.6, 136.8, 135.2, 134.5, 132.3, (130.3, 130.2)(1C), (129.7, 129.8) (1C), (128.2, 127.9) (1C), 127.7 (2C), (123.7, 123.5)(1C) 120.36, 87.11, 18.37 (2C); HRMS: [M+H]+ calcd for C17H15NO 250.1226, found250.1227。
(Z)-3-methylene-N-(m-tolyl)isobenzofuran-1(3H)-imine (I-3). Colorlessoil (37.1 mg, 79%); 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 7.6 Hz, 1H), 7.64(d, J = 7.6 Hz, 1H), 7.56 (dt, J = 19.6, 6.8 Hz, 2H), 7.31 – 7.23 (m, 1H),7.17 (d, J = 7.6 Hz, 2H), 6.98 (d, J = 7.6 Hz, 1H), 4.99 (t, J = 2.4 Hz, 2H),2.38 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.1, 153.7, 145.6, 138.5, 136.2,132.1, 130.8, 130.1, 128.5, 125.5, 124.2, 123.5, 120.5, 120.2, 87.1, 21.5;HRMS: [M+H]+ calcd for C16H13NO 236.1070, found 236.1071。
(Z)-N-(4-methoxyphenyl)-3-methyleneisobenzofuran-1(3H)-imine (I-5).White solid (39.2 mg, 78%);1H NMR (400 MHz, CDCl3) δ 7.96 (dt, J = 7.2, 1.2Hz, 1H), 7.65 (dt, J = 8.0, 1.2 Hz, 1H), 7.56 (dtd, J= 18.4, 7.2, 1.2 Hz,2H), 7.50 – 7.41 (m, 2H), 6.96 – 6.90 (m, 2H), 5.06 – 4.97 (m, 2H), 3.84 (s,3H); 13C NMR (100 MHz, CDCl3) δ 157.0, 155.2, 152.8, 138.5, 135.9, 131.8,131.2, 130.1, 125.7 (2C), 123.4, 120.2, 114.0 (2C), 86.6, 55.4; HRMS: [M+H]+calcd for C16H13NO2 252.1019, found 252.1020。
(Z)-N-(4-fluorophenyl)-3-methyleneisobenzofuran-1(3H)-imine (I-6).Colorless oil (39.2 mg, 82%); 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J= 7.6 Hz,1H), 7.65 (d, J = 7.6 Hz, 1H), 7.57 (dt, J= 22.0, 7.2 Hz, 2H), 7.39 (dd, J =8.8, 5.2 Hz, 2H), 7.06 (t, J= 8.8 Hz, 2H), 5.02 (s, 2H); 13C NMR (100 MHz,CDCl3) δ 161.3, 158.9, 155.1, 153.8, (141.6, 141.5) (1C), 136.1, 132.2,130.7, 130.2, (125.6, 125.5) (1C), 123.5, 120.3, 115.5, 115.3, 87.2; 19F NMR(376 MHz, CDCl3) δ -118.1; HRMS: [M+H]+ calcd for C15H10FNO 240.0819, found240.0823。
(Z)-N-benzyl-3-methyleneisobenzofuran-1(3H)-imine (I-7). White solid(37.6 mg, 78%); 1H NMR (400 MHz, CDCl3); δ 7.93 (d, J = 7.6 Hz, 1H), 7.64 (d,J = 7.6 Hz, 1H), 7.57 (t, J = 7.2 Hz, 1H), 7.54 – 7.46 (m, 3H), 7.39 (t, J =7.6 Hz, 2H), 7.32 – 7.28 (m, 1H), 5.06 – 4.96 (m, 2H), 4.90 (s, 2H); 13C NMR(100 MHz, CDCl3) δ 155.4, 155.0, 140.2, 136.5, 131.6, 130.5, 130.0, 128.4(2C), 127.9 (2C), 126.7, 123.2, 120.2, 85.7, 51.7; HRMS: [M+H]+ calcd forC16H13NO 236.1070, found 236.1077。
(Z)-6-methyl-3-methylene-N-phenylisobenzofuran-1(3H)-imine (I-9).Colorless oil (37.6 mg, 80%); 1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.52 (d,J = 8.0 Hz, 1H), 7.37 (d, J = 5.6 Hz, 5H), 7.15 (tt, J = 6.4, 2.4 Hz, 1H),4.93 (q, J = 2.8 Hz, 2H), 2.47 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.2,154.0, 145.7, 140.7, 133.8, 133.4, 131.1, 128.7(2C), 124.6, 123.7 (2C),123.6, 120.1, 86.3, 21.6; HRMS: [M+H]+ calcd for C16H13NO 236.1070, found236.1071。
(Z)-3-methylene-5-nitro-N-phenylisobenzofuran-1(3H)-imine (I-10).Light yellow solid (47.3 mg, 89%); 1H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 2.0Hz, 1H), 8.39 (dd, J = 8.4, 2.0 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.46 –7.36 (m, 4H), 7.22 (tt, J= 6.0, 2.4 Hz, 1H), 5.19 (s, 2H); 13C NMR (100 MHz,CDCl3) δ 153.5, 151.3, 150.6, 144.6, 137.0, 135.8, 128.9 (2C), 125.7, 125.2,124.9, 124.1 (2C), 116.1, 89.8; HRMS: [M+H]+ calcd for C15H10N2O3 267.0764,found 267.0763。
(Z)-1-methylene-N-phenylnaphtho[1,2-c]furan-3(1H)-imine (I-11). Whitesolid (47.7 mg, 88%); 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 7.8 Hz, 1H), 8.03– 7.95 (m, 3H), 7.72 – 7.57 (m, 2H), 7.47 – 7.35 (m, 4H), 7.22-7.13 (m, 1H),5.45 (d, J = 3.2 Hz, 1H), 5.32 (d, J= 3.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ155.8, 154.1, 145.8, 135.7, 132.1, 131.8, 130.8, 129.7, 128.8 (2C), 128.3,127.8, 127.0, 124.7, 124.0 (2C), 123.7, 119.5, 92.2; HRMS: [M+H]+ calcd forC19H13NO 272.1070, found 272.1271。
(Z)-7-methyl-3-methylene-N-phenylisobenzofuran-1(3H)-imine (I-12).Colorless oil (32.0 mg, 68%); 1H NMR (400 MHz, CDCl3) δ 7.45 (q, J = 8.0 Hz,2H), 7.36 (d, J = 7.2 Hz, 2H), 7.30 (d, J = 8.0 Hz, 3H), 7.14 (t, J = 7.2 Hz,1H), 4.95 – 4.90 (m, 2H), 2.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.9,154.2, 146.3, 137.8, 136.7, 132.0, 131.6, 128.7 (2C), 127.9, 124.3, 123.4(2C), 117.6, 86.1, 18.6; HRMS: [M+H]+ calcd for C16H13NO 236.1070, found236.1071。
(Z)-4-methyl-3-methylene-N-phenylisobenzofuran-1(3H)-imine (I-13).Colorless oil (37.6 mg, 80%); 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 7.6 Hz,1H), 7.42 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 5.6 Hz, 5H), 7.15 (tt, J = 6.0,2.8 Hz, 1H), 5.12 (d, J = 3.2 Hz, 1H), 4.97 (d, J= 3.0 Hz, 1H), 2.52 (s, 3H);13C NMR (100 MHz, CDCl3) δ 155.7, 154.1, 145.9, 134.1, 133.8, 133.5, 131.6,130.0, 128.7 (2C), 124.5, 123.7 (2C), 121.4, 91.3, 20.0; HRMS: [M+H]+ calcdfor C16H13NO 236.1070, found 236.1072。
(Z)-3-((Z)-4-chlorobenzylidene)-N-phenylisobenzofuran-1(3H)-imine (I-14). White solid (46.3 mg, 70%); 1H NMR (400 MHz, CDCl3) δ 8.37 (d, J = 8.0Hz, 1H), 7.55 (t, J = 7.2, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.41 (dt, J = 15.6,7.8 Hz, 3H), 7.31 (t, J = 9.6 Hz, 3H), 7.22 (d, J = 7.6 Hz, 2H), 7.14 (t, J =7.6 Hz, 1H), 6.69 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 150.6, 149.5, 146.7,135.4, 133.7, 132.5, 130.8, 129.5, 128.9 (2C), 128.8 (2C), 128.4, 127.6,125.9 (2C), 125.7, 123.7, 122.3 (2C), 101.2; HRMS: [M+H]+ calcd for C21H14ClNO332.0837, found 332.0838。
(1Z,3Z)-3-butylidene-N-phenylisobenzofuran-1(3H)-imine (I-15).Colorless oil; (Z:E = 6.7:1); 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 7.6 Hz,1H), 7.59 – 7.55 (m, 2H), 7.49 – 7.42 (m, 3H), 7.42 – 7.34 (m, 2H), 7.19 –7.10 (m, 1H), 5.43 (t, J = 7.6 Hz, 1H), 2.37 (q, J = 7.6 Hz, 2H), 1.52 (dt, J= 14.8, 7.2 Hz, 2H), 0.97 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ154.2, 148.4, 145.8, 136.7, 132.0, 130.3, 129.1, 128.7 (2C), 124.6, 124.2(2C), 123.6, 119.3, 106.7, 29.7, 19.2, 14.1. HRMS: [M+H]+ calcd for C18H17NO264.1383, found 264.1384。
Claims (1)
1.式I所示的苯并呋喃亚胺内酯衍生物的合成方法，其特征在于：
以式II所示的邻烯烃苯甲酰胺类分子为底物，加入催化当量的碘试剂/氧化剂催化体系，以路易斯酸三氟化硼乙醚为添加剂，乙腈为溶剂，室温反应一步构建式I所示的苯并呋喃亚胺内酯化合物，所述碘试剂为对甲基碘苯，氧化剂为间氯过氧苯甲酸，
其中：R选自苯基、苄基、C1~C3的烷基，或取代的苯基或苄基，所述取代的苯基或苄基中的取代基为C1~C3的烷基、C1~C3的烷氧基、卤素、硝基；
R1选自氢、C1~C3的烷基、C1~C3的烷氧基、卤素、硝基；
R2选自氢，C1~C3的烷基，C1~C3的烷氧基、卤素、硝基、苯基、苄基，或取代的苯基或苄基，所述取代的苯基或苄基中的取代基为C1~C3的烷基、C1~C3的烷氧基、卤素、硝基。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911323588.3A CN111072611B (zh) | 2019-12-20 | 2019-12-20 | 一种苯并呋喃亚胺内酯衍生物的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911323588.3A CN111072611B (zh) | 2019-12-20 | 2019-12-20 | 一种苯并呋喃亚胺内酯衍生物的合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111072611A CN111072611A (zh) | 2020-04-28 |
| CN111072611B true CN111072611B (zh) | 2023-03-24 |
Family
ID=70316084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911323588.3A Active CN111072611B (zh) | 2019-12-20 | 2019-12-20 | 一种苯并呋喃亚胺内酯衍生物的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111072611B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014234376A (ja) * | 2013-06-04 | 2014-12-15 | 国立大学法人 名古屋工業大学 | トリフルオロメタンスルホニル基を含む超原子価ヨウ素イリドを用いるトリフルオロメチルチオ化法 |
-
2019
- 2019-12-20 CN CN201911323588.3A patent/CN111072611B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014234376A (ja) * | 2013-06-04 | 2014-12-15 | 国立大学法人 名古屋工業大学 | トリフルオロメタンスルホニル基を含む超原子価ヨウ素イリドを用いるトリフルオロメチルチオ化法 |
Non-Patent Citations (1)
| Title |
|---|
| Synthesis of lennoxamine via the intramolecular cyclization of alkynylamide;Yuji KOSEKI 等;《Chem. Pharm. Bull.》;19951231;第43卷(第9期);1604-1606 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111072611A (zh) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110143918A (zh) | 3,4-二氢-3-(2-羟基苯甲酰)-2(1h)-喹啉酮活性骨架及合成方法和应用 | |
| CN109081807B (zh) | 一种制备三取代4-氨基咔唑类和二取代1-氨基二苯并[b,d]噻吩类化合物的方法 | |
| CN110183378A (zh) | 一种烟酰胺的衍生物及其催化合成方法 | |
| WO2005000803A2 (ja) | 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法 | |
| CN110437129B (zh) | 一种合成3-醚基异吲哚啉酮类化合物的简单方法 | |
| CN105820174B (zh) | 一种多取代噻吩并吲哚衍生物的制备方法 | |
| CN111072611B (zh) | 一种苯并呋喃亚胺内酯衍生物的合成方法 | |
| CN103664821B (zh) | 一种基于邻氨基苯硫酚环化的苯并噻唑类化合物制备方法 | |
| CN102690227A (zh) | 一种光学活性四氢吡啶衍生物及其制备方法 | |
| CN112824412B (zh) | 手性1′H-螺[吲哚啉-3,4′-吡喃并[2,3-c]吡唑]-2-酮类化合物 | |
| CN109320503B (zh) | 苯并咪唑炔胺类化合物的无金属一锅合成方法 | |
| CN105481867A (zh) | 三步接力催化构建手性螺环氧化吲哚及其合成方法和应用 | |
| CN111440166A (zh) | 多取代吲嗪类衍生物及其制备方法 | |
| CN113087689B (zh) | 5-氨基-γ-内酯衍生物的简便合成方法 | |
| CN103709101B (zh) | 一类renieramycin G的合成中间体及其制备方法 | |
| CN110981790B (zh) | 一种1,4-二氢吡啶类衍生物及其合成方法 | |
| CN103159773B (zh) | 具有手性螺环内酯吡咯环结构片段的多环衍生物及其合成方法 | |
| CN111170926B (zh) | 一种催化不对称合成手性β-炔基-β-氨基酮衍生物的方法 | |
| CN109721523B (zh) | 一种二氢吲哚衍生物及其制备方法 | |
| CN108610306B (zh) | 一种2h-1,4-噻嗪-3(4h)-酮衍生物的合成方法 | |
| CN109400629B (zh) | 吲哚螺噁嗪杂环类化合物及其制备方法 | |
| KR100718166B1 (ko) | 구리 촉매하의 삼성분 짝지움 반응에 의한ｎ-술포닐아미딘의 제조방법 | |
| CN108276420B (zh) | 一种8,13-二氢苯并[5,6]色烯并[2,3-b]吲哚类化合物及其合成方法 | |
| CN111303096A (zh) | 一种多取代1,3-二氢萘并[2,3-c]呋喃衍生物的合成方法 | |
| CN117088826B (zh) | 一种可见光促进的多取代噁唑的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |